HLB’s Rivoceranib Gains Attention as a New Treatment Option for Adenoid Cystic Carcinoma

· No standard treatment for ACC, rivoceranib shows promise
· Expanding treatment options for rare cancers

 

HLB's rivoceranib gains attention as a new treatment option for ACC (IT Times)

SEOUL, South Korea, February 12, 2025 (IT Times) - HLB's anti-ancer drug Rivoceranib, currently under development as a treatment for liver cancer, is emerging as a promising new option for adenoid cystic carcinoma (ACC), a rare cancer with significant unmet medical needs.

The company, through its U.S. subsidiary Elevar Therapeutics, is currently in the process of securing FDA approval for Rivoceranib as a liver cancer treatment. Based on the PDUFA (Prescription Drug User Fee Act) date, the FDA’s final decision on the drug's approval is expected no later than March 20.

If approved for liver cancer, HLB plans to pursue the inclusion of Rivoceranib in the NCCN (National Comprehensive Cancer Network) guidelines for both liver cancer and ACC. The NCCN guidelines serve as a crucial reference for oncologists when prescribing cancer treatments. Drugs that demonstrate scientifically proven therapeutic effects and receive approval for one cancer type often find it easier to be listed in the NCCN guidelines for other indications.

Read more: https://www.ittimes.com/news/articleView.html?idxno=64584

HLB’s Rivoceranib Gains Attention as a New Treatment Option for Adenoid Cystic Carcinoma - IT타임스